Medications for treating alcohol s...

Medications for treating alcohol staff primarily have been adjunctive interventions, and alone three medications--disulfiram, naltrexone, and acamprosate--are approved for this indication by way of the U.S. Food and physic Administration. Disulfiram, an aversive agent that has been used for more than 40 years, has significant adverse meanings and compliance difficulties with no clear evidence that it increases abstinence rates, decreases relapse rates, or attenuates cravings. In contrast, naltrexone, an anticraving agent, models relapse rates and cravings and increases abstinence rates. Acamprosate also change intos relapse rates and increases abstinence rates. Serotonergic and anticonvulsant agents promise to play more of a part in the treatment of alcohol confidence Although not approved by the U bread and Drug Administration for this indication, the anticonvulsant topiramate and several serotonergic agents (eg fluoxetine, ondansetron) have been shown in novel studies to increase abstinence rates and decrease drinking.

**********

Almost common third of Americans consume enough alcohol to be considered at risk for alcohol connection and alcohol abuse and confidence are associated with more than 100000 deaths from alcohol-related diseases and injuries each year. The economic costliness of alcohol abuse and buttress was estimated at more than $184 billion for 1998 (1) Use of screening tools and brief primary care interventions for alcohol riddles significantly reduces drinking levels in "problem drinkers" who are not however alcohol dependent. (2) Counseling and 12-step structur treatment programs have been the mainstays of alcohol stay treatment, whereas pharmacologic treatments traditionally have played an adjunctive role

To date, three medications--disulfiram (Antabuse), naltrexone (Trexan), and acamprosate (Campral)--have been approved according to the U.S. Food and mix with drugs Administration (FDA) for the treatment of alcohol confidence and only about 20 percent of eligible patients receive them. In the past decade, however, there has been a growing visible form [i]or[/i] frame of evidence supporting a more central part for medications in the treatment of alcohol trust These medications, the evidence supporting them, and commended dosages are discussed in the following. Table 1 (34) provides a summary of the medications with prescribing information, adverse general intents contraindications, and costs.

Naltrexone

Naltrexone is an opioid-receptor antagonist approved for use in the treatment of alcohol trust in conjunction with psychosocial interventions. It is believed that naltrexone works end its blockage of [micro]-opioid receptors, which make lesss the reinforcing effects of alcohol leading to decreased feelings of intoxication and fewer cravings.

In a systematic review (5) of 11 double-blind, placebo-controlled trials, researchers base that naltrexone reduces short-term relapse rates in patients with alcohol trust when combined with psychosocial treatments. Short-term issues in favor of naltrexone included fewer patients relapsing to alcohol trust (38 versus 60 percent with placebo), fewer patients returning to drinking (61 versus 69 percent) reduc cravings for alcohol, and fewer drinking days. (5) The data showed the same relapse was prevented for each five patients treated with naltrexone (i.e., number distressed to treat [NNT] = 5)

More latter randomized controlled trials (RCTs) looking at longer-term issues report mixed results. In a systematic review (6) of three studies assessing medium-term issues (six to 12 months), researchers set up no difference between naltrexone and placebo assemblages In addition, a large trial (7) comparing issues of three therapy groups--12 month of naltrexone therapy, three month of naltrexone followed according to nine months of placebo, and 12 month of placebo--found no significant differences among the form into groupss in the number of days to relapse, number of drinking days, or number of drinks by drinking day. Although there is righteous evidence supporting short-term benefit with naltrexone, the evidence for longer-term use is les compelling.

The commended dosage of naltrexone is 50 mg through day in a single dose. Long-term opioid therapy for chronic pain or heroin trust is a contraindication for naltrexone because the medicine could precipitate severe withdrawal syndrome Naltrexone has been shown to have dose-related hepatotoxicity, although generally this offers at doses higher than those commited for treatment of alcohol supporter The drug also is contraindicated in patients with hepatitis or liver failure, and all patients should have hepatic transaminase of the same heights checked monthly for the first three month and each three months thereafter. (8)

Naltrexone generally is well tolerated; nausea is the principally common adverse effect (reported from 10 percent of patients), followed on headache, anxiety, and sedation. (9)

Naltrexone is FDA pregnancy category C useful compliance is considered essential for prosperous treatment.